Kamada to Announce Second Quarter and First Half Ended June 30, 2025 Financial Results on August 13, 2025
Kamada (NASDAQ: KMDA), a commercial stage biopharmaceutical company specializing in rare and serious conditions through plasma-derived products, has scheduled its Q2 and H1 2025 financial results announcement for August 13, 2025, before U.S. markets open.
The company will host an investment community conference call at 8:30 AM ET on the same day, where management will discuss results and take questions. Investors can join via phone or webcast, with specific dial-in numbers provided for U.S., Israeli, and international participants.
Kamada (NASDAQ: KMDA), un'azienda biofarmaceutica in fase commerciale specializzata in condizioni rare e gravi attraverso prodotti derivati dal plasma, ha programmato l'annuncio dei risultati finanziari del secondo trimestre e del primo semestre 2025 per il 13 agosto 2025, prima dell'apertura dei mercati statunitensi.
La società terrà una conference call per la comunità degli investitori alle 8:30 AM ET nello stesso giorno, durante la quale la direzione discuterà i risultati e risponderà alle domande. Gli investitori potranno partecipare tramite telefono o webcast, con numeri di accesso specifici forniti per partecipanti dagli Stati Uniti, Israele e internazionali.
Kamada (NASDAQ: KMDA), una compañía biofarmacéutica en etapa comercial especializada en condiciones raras y graves mediante productos derivados del plasma, ha programado el anuncio de resultados financieros del segundo trimestre y primer semestre de 2025 para el 13 de agosto de 2025, antes de la apertura de los mercados en EE.UU.
La empresa realizará una llamada de conferencia para la comunidad inversora a las 8:30 AM ET el mismo día, donde la dirección discutirá los resultados y responderá preguntas. Los inversores podrán unirse por teléfono o webcast, con números de acceso específicos para participantes de EE.UU., Israel e internacionales.
Kamada (NASDAQ: KMDA)는 희귀하고 중증 질환을 혈장 유래 제품으로 전문으로 하는 상업 단계의 바이오제약 회사로, 2025년 8월 13일 미국 시장 개장 전에 2025년 2분기 및 상반기 재무실적 발표를 예정하고 있습니다.
회사는 같은 날 오전 8시 30분(동부시간)에 투자자 대상 컨퍼런스 콜을 개최하여 경영진이 실적을 설명하고 질문에 답변할 예정입니다. 투자자들은 미국, 이스라엘 및 국제 참가자를 위한 별도의 전화 접속 번호를 통해 전화 또는 웹캐스트로 참여할 수 있습니다.
Kamada (NASDAQ : KMDA), une société biopharmaceutique en phase commerciale spécialisée dans les affections rares et graves via des produits dérivés du plasma, a programmé l'annonce de ses résultats financiers du deuxième trimestre et du premier semestre 2025 pour le 13 août 2025, avant l'ouverture des marchés américains.
La société organisera une conférence téléphonique destinée à la communauté des investisseurs à 8h30 ET le même jour, au cours de laquelle la direction discutera des résultats et répondra aux questions. Les investisseurs pourront participer par téléphone ou via un webcast, avec des numéros d'accès spécifiques fournis pour les participants américains, israéliens et internationaux.
Kamada (NASDAQ: KMDA), ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf seltene und schwere Erkrankungen mit plasmaabgeleiteten Produkten spezialisiert hat, hat die Veröffentlichung der Finanzergebnisse für das zweite Quartal und das erste Halbjahr 2025 für den 13. August 2025 geplant, und zwar vor der Öffnung der US-Märkte.
Das Unternehmen wird am selben Tag um 8:30 Uhr ET eine Telefonkonferenz für die Investment-Community abhalten, bei der das Management die Ergebnisse besprechen und Fragen beantworten wird. Investoren können per Telefon oder Webcast teilnehmen, wobei spezifische Einwahlnummern für Teilnehmer aus den USA, Israel und international bereitgestellt werden.
- None.
- None.
Company to Host Conference Call at 8:30am ET
REHOVOT, Israel, and HOBOKEN, N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the second quarter and first half ended June 30, 2025, prior to the open of the U.S. financial markets on Wednesday, August 13, 2025.
Kamada management will host an investment community conference call on Wednesday, August 13, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the call by dialing 1-877-413-7208 (from within the U.S.), 1-809-406-247 (from Israel), or 1-201-689-8555 (International) using conference I.D. 13754604. The call will be webcast live on the internet at: https://viavid.webcasts.com/starthere.jsp?ei=1726126&tp_key=61b4d50ef5
About Kamada
Kamada Ltd. (the “Company”) is a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field. The Company’s strategy is focused on driving profitable growth through four primary growth pillars: First, organic growth from its commercial activities, including continued investment in the commercialization and life cycle management of its proprietary products, which include six FDA-approved specialty plasma-derived products: KEDRAB®, CYTOGAM®, GLASSIA®, WINRHO SDF®, VARIZIG® and HEPAGAM B®, as well as KAMRAB®, KAMRHO (D)® and two types of equine-based anti-snake venom products, and the products in the distribution segment portfolio, mainly through the launch of several biosimilar products in Israel. Second: the Company aims to secure significant new business development, in-licensing, collaboration and/or merger and acquisition opportunities, which are anticipated to enhance the Company’s marketed products portfolio and leverage its financial strength and existing commercial infrastructure to drive long-term growth. Third: the Company is expanding its plasma collection operations to support revenue growth through the sale of normal source plasma to other plasma-derived manufacturers, and to support its increasing demand for hyper-immune plasma. The Company currently owns three operating plasma collection centers in the United States, in Beaumont Texas, Houston Texas, and San Antonio, Texas. Lastly, the Company is leveraging its manufacturing, research and development expertise to advance the development and commercialization of additional product candidates, targeting areas of significant unmet medical need, with the lead product candidate Inhaled AAT, for which the Company is continuing to progress the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial. FIMI Opportunity Funds, the leading private equity firm in Israel, is the Company’s controlling shareholder, beneficially owning approximately
CONTACTS:
Chaime Orlev
Chief Financial Officer
IR@kamada.com
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
britchie@LifeSciAdvisors.com
FAQ
When will Kamada (KMDA) release its Q2 2025 earnings?
What time is Kamada's Q2 2025 earnings conference call?
How can investors join Kamada's Q2 2025 earnings call?
What does Kamada (KMDA) specialize in?
